CN105044337A - 用于诊断肺炎链球菌的试验 - Google Patents
用于诊断肺炎链球菌的试验 Download PDFInfo
- Publication number
- CN105044337A CN105044337A CN201510346907.8A CN201510346907A CN105044337A CN 105044337 A CN105044337 A CN 105044337A CN 201510346907 A CN201510346907 A CN 201510346907A CN 105044337 A CN105044337 A CN 105044337A
- Authority
- CN
- China
- Prior art keywords
- pcpa
- phte
- antibody
- phtd
- ply
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims description 18
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims description 3
- 238000003556 assay Methods 0.000 title abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 84
- 102000036639 antigens Human genes 0.000 claims abstract description 84
- 108091007433 antigens Proteins 0.000 claims abstract description 84
- 101100453077 Botryococcus braunii HDR gene Proteins 0.000 claims abstract description 73
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 37
- 230000004044 response Effects 0.000 claims description 31
- 239000000523 sample Substances 0.000 claims description 27
- 108060003951 Immunoglobulin Proteins 0.000 claims description 17
- 102000018358 immunoglobulin Human genes 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 12
- 241000194017 Streptococcus Species 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- 238000002493 microarray Methods 0.000 claims 1
- 238000003118 sandwich ELISA Methods 0.000 claims 1
- 230000000935 anti-streptococcal effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 48
- 210000002966 serum Anatomy 0.000 description 33
- 230000035945 sensitivity Effects 0.000 description 27
- 238000003745 diagnosis Methods 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 241001478240 Coccus Species 0.000 description 12
- 230000008485 antagonism Effects 0.000 description 12
- 208000035109 Pneumococcal Infections Diseases 0.000 description 11
- 210000001989 nasopharynx Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 8
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 208000022218 streptococcal pneumonia Diseases 0.000 description 8
- 101710183389 Pneumolysin Proteins 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000009268 pathologic speech processing Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 101710153593 Albumin A Proteins 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- -1 PhtE Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 208000034657 Convalescence Diseases 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 102400000368 Surface protein Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 241000158526 Nasalis Species 0.000 description 3
- 206010036590 Premature baby Diseases 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010084884 GDP-mannose transporter Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241001113283 Respirovirus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000022760 infectious otitis media Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- GHODABZPVZMWCE-FXQIFTODSA-N Asp-Glu-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O GHODABZPVZMWCE-FXQIFTODSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 101710164918 Choline-binding protein Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940085771 feverall Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000009596 phenolsulfonphthalein test Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56944—Streptococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
- G01N2333/3156—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae [Pneumococcus]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6337608P | 2008-02-01 | 2008-02-01 | |
| US61/063376 | 2008-02-01 | ||
| CN200980103761.7A CN101952728B (zh) | 2008-02-01 | 2009-02-02 | 用于诊断肺炎链球菌的试验 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980103761.7A Division CN101952728B (zh) | 2008-02-01 | 2009-02-02 | 用于诊断肺炎链球菌的试验 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105044337A true CN105044337A (zh) | 2015-11-11 |
Family
ID=40912214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510346907.8A Pending CN105044337A (zh) | 2008-02-01 | 2009-02-02 | 用于诊断肺炎链球菌的试验 |
| CN200980103761.7A Expired - Fee Related CN101952728B (zh) | 2008-02-01 | 2009-02-02 | 用于诊断肺炎链球菌的试验 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980103761.7A Expired - Fee Related CN101952728B (zh) | 2008-02-01 | 2009-02-02 | 用于诊断肺炎链球菌的试验 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8404457B2 (https=) |
| EP (1) | EP2235531B1 (https=) |
| JP (1) | JP5697991B2 (https=) |
| KR (1) | KR101667620B1 (https=) |
| CN (2) | CN105044337A (https=) |
| AU (1) | AU2009208299B2 (https=) |
| BR (1) | BRPI0907010A2 (https=) |
| CA (1) | CA2708209A1 (https=) |
| IL (1) | IL206437A (https=) |
| MX (1) | MX2010008514A (https=) |
| WO (1) | WO2009094779A1 (https=) |
| ZA (1) | ZA201004533B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007512006A (ja) * | 2003-11-10 | 2007-05-17 | ザ ユーエービー リサーチ ファウンデーション | 細菌輸送およびｃｎｓ侵襲を低減させるための組成物およびこの組成物を使用する方法 |
| WO2008022299A1 (en) * | 2006-08-17 | 2008-02-21 | The Uab Research Foundation | Diagnosing pneumococcal pneumonia |
| EP2235531B1 (en) * | 2008-02-01 | 2015-01-14 | Sanofi Pasteur Limited | Assay for diagnosing streptococcus pneumoniae |
| AU2010335970B2 (en) * | 2009-12-22 | 2016-11-03 | Sanofi Pasteur Limited | Immunogenic compositions |
| CN102939105B (zh) * | 2009-12-22 | 2016-11-16 | 赛诺菲巴斯德有限公司 | 免疫原性组合物和相关的方法 |
| MX2013006255A (es) | 2010-12-03 | 2015-08-05 | Sanofi Pasteur Ltd | Composicion para inmunizacion contra streptococcus pneumoniae. |
| CN104181302B (zh) * | 2014-08-18 | 2016-01-06 | 湖北工业大学 | 基于磁性分离和多色量子点标记的抗人肺炎链球菌IgM、IgG抗体快速共检的方法和试剂盒 |
| KR20200097134A (ko) * | 2019-02-07 | 2020-08-18 | 에스케이바이오사이언스(주) | 교차반응이 없는 폐렴구균 항혈청 및 이의 제조방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022167A2 (en) * | 2000-09-15 | 2002-03-21 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus penumoniae |
| WO2004020609A2 (en) * | 2002-08-30 | 2004-03-11 | Tufts University | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716432B1 (en) * | 1988-12-16 | 2004-04-06 | James Cleland Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| US7078042B2 (en) | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| US6245335B1 (en) * | 1996-05-01 | 2001-06-12 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
| GB0213622D0 (en) * | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| EP2311988A1 (en) * | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigens |
| JP2005110545A (ja) * | 2003-10-06 | 2005-04-28 | Meiji Seika Kaisha Ltd | 呼吸器感染症起因菌の迅速検出法およびそのキット |
| US7713715B2 (en) * | 2005-09-06 | 2010-05-11 | University Of Tennessee Research Foundation | Method for diagnosing infections |
| EP1882939A1 (en) * | 2006-07-27 | 2008-01-30 | The Jordanian Pharmaceutical Manufacturing Co. | Urinary immunochromatographic antigen detection cup |
| WO2008022299A1 (en) * | 2006-08-17 | 2008-02-21 | The Uab Research Foundation | Diagnosing pneumococcal pneumonia |
| EP2235531B1 (en) | 2008-02-01 | 2015-01-14 | Sanofi Pasteur Limited | Assay for diagnosing streptococcus pneumoniae |
-
2009
- 2009-02-02 EP EP09705818.4A patent/EP2235531B1/en not_active Not-in-force
- 2009-02-02 CN CN201510346907.8A patent/CN105044337A/zh active Pending
- 2009-02-02 JP JP2010544547A patent/JP5697991B2/ja not_active Expired - Fee Related
- 2009-02-02 WO PCT/CA2009/000119 patent/WO2009094779A1/en not_active Ceased
- 2009-02-02 US US12/865,198 patent/US8404457B2/en not_active Expired - Fee Related
- 2009-02-02 AU AU2009208299A patent/AU2009208299B2/en not_active Ceased
- 2009-02-02 CA CA2708209A patent/CA2708209A1/en not_active Abandoned
- 2009-02-02 KR KR1020107017033A patent/KR101667620B1/ko not_active Expired - Fee Related
- 2009-02-02 MX MX2010008514A patent/MX2010008514A/es unknown
- 2009-02-02 BR BRPI0907010-9A patent/BRPI0907010A2/pt not_active Application Discontinuation
- 2009-02-02 CN CN200980103761.7A patent/CN101952728B/zh not_active Expired - Fee Related
-
2010
- 2010-06-17 IL IL206437A patent/IL206437A/en not_active IP Right Cessation
- 2010-06-25 ZA ZA2010/04533A patent/ZA201004533B/en unknown
-
2013
- 2013-03-01 US US13/782,462 patent/US9535064B2/en not_active Expired - Fee Related
-
2016
- 2016-12-19 US US15/382,827 patent/US20170102385A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022167A2 (en) * | 2000-09-15 | 2002-03-21 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus penumoniae |
| CA2421998A1 (en) * | 2000-09-15 | 2002-03-21 | Smithkline Beecham Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| CN1477970A (zh) * | 2000-09-15 | 2004-02-25 | ʷ��˹���������������﹫˾ | 疫苗 |
| WO2004020609A2 (en) * | 2002-08-30 | 2004-03-11 | Tufts University | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection |
Non-Patent Citations (1)
| Title |
|---|
| GLOVER, DAVID TAWAYNE: "Pneumococcal choline-binding protein A: Its role in virulence and its utility as a Streptococcus pneumoniae vaccine antigen", 《阿拉巴马大学伯明翰分校博士学位论文》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009094779A1 (en) | 2009-08-06 |
| MX2010008514A (es) | 2010-09-30 |
| AU2009208299A1 (en) | 2009-08-06 |
| KR20100117588A (ko) | 2010-11-03 |
| IL206437A (en) | 2014-08-31 |
| AU2009208299B2 (en) | 2015-01-22 |
| CN101952728B (zh) | 2016-05-11 |
| US20140349863A1 (en) | 2014-11-27 |
| EP2235531A1 (en) | 2010-10-06 |
| CN101952728A (zh) | 2011-01-19 |
| EP2235531A4 (en) | 2011-01-12 |
| KR101667620B1 (ko) | 2016-10-19 |
| US20170102385A1 (en) | 2017-04-13 |
| US9535064B2 (en) | 2017-01-03 |
| EP2235531B1 (en) | 2015-01-14 |
| CA2708209A1 (en) | 2009-08-06 |
| ZA201004533B (en) | 2011-04-28 |
| BRPI0907010A2 (pt) | 2015-07-07 |
| US8404457B2 (en) | 2013-03-26 |
| JP5697991B2 (ja) | 2015-04-08 |
| IL206437A0 (en) | 2010-12-30 |
| US20110130300A1 (en) | 2011-06-02 |
| JP2011511275A (ja) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12385918B2 (en) | IgA antibodies and kits capable of specifically recognizing RBD protein | |
| US20170102385A1 (en) | Assay for Diagnosing Streptococcus Pneumoniae | |
| TWI392735B (zh) | 口蹄疫融合瘤細胞株、其單株抗體、及包含該單株抗體的ｅｌｉｓａ檢測試劑及套組 | |
| US20070092938A1 (en) | Diagnostics for sars virus | |
| US11768202B2 (en) | Method of detecting anti-Ri in a subject with a previous streptococcal infection | |
| JP2011511275A5 (https=) | ||
| US7824909B2 (en) | Recombinant antigens for the detection of coxiella burnetii | |
| JP5033127B2 (ja) | 単純ヘルペスウイルス２型を検出するための方法および組成物 | |
| EP2023142A1 (en) | Immunoassay utilizing recombinant nucleocapsid-proteins for detection of antibodies to human coronaviruses | |
| KR101032956B1 (ko) | 수청바이러스 유래 뉴클레오캡시드 단백질을 이용하여 신증후출혈열 특이 ＩｇＭ과 ＩｇＧ를 검출하는 신속 진단 키트 | |
| CN112646006B (zh) | 一种用于covid-19轻重症分型诊断的标志物抗原表位多肽及其应用 | |
| EP4476265A1 (en) | Anti-her2/neu antibodies and methods of use | |
| KR101587859B1 (ko) | 폐렴연쇄상구균의 NagA 단백질을 포함하는 폐렴연쇄상구균의 감염 진단용 조성물 | |
| HK40104460A (zh) | 重组抗体、包含重组抗体的套组及其用途 | |
| CN117186217A (zh) | 抗muc5b蛋白的抗体 | |
| CN121930338A (zh) | 一种重组人源化抗Cpn IgM单克隆抗体、制备方法及应用 | |
| CN101031587A (zh) | 孢子特异性抗体 | |
| WO2015132588A1 (en) | Assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151111 |